Aventis Launching Ketek With 1,800-Person Primary Care Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The sales force will begin detailing Ketek Aug. 2. The company has blockbuster expectations for the antibiotic, particularly in light of the upcoming patent expiration for Pfizer’s Zithromax.
You may also be interested in...
Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.
Roxane Receives First Generic Approval For Abbott’s Biaxin
ANDA for 250 mg and 500 mg tablets receives full approval from FDA. Abbott says compound patent runs until 2005.
Aventis Ketek Approved By FDA; Antibiotic Launch Planned For Late July
Telithromycin is approved for the treatment of acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and mild-to-moderate community acquired pneumonia. Phase IV commitments include pediatric studies in CAP and sinusitis.